POC - Transfusion Algorithm Cardiac Study (TACS)
Blood Conservation in Cardiac Surgery Using a Novel Transfusion Algorithm Based on Point-of-care Testing-A Stepped-wedge Cluster Randomized Controlled Trial
This multi-centre study will provide sound, generalizable data on the effectiveness of a POC-based algorithm to determine to what extent this guideline can reduce blood product transfusions. Investigators will study outcomes in 7000 patients undergoing heart surgery at 10 participating hospitals. The proposed trial addresses several important research and clinical issues and has the potential to markedly improve the transfusion management and surgical care in general of cardiac surgery patients.
The intervention will be a novel POC-based algorithm that has been shown in a pilot study by us to be associated with a substantial reduction in blood product transfusions. The algorithm will employ viscoelastic and aggregometric POC-tests and an objective measure of blood loss. The primary outcome will be avoidance of red blood cell transfusion during hospitalization. The study has a 90% power to detect a 12% increase in avoidance rate. Secondary outcomes will include avoidance of red blood cell use and other blood products (plasma, platelets, and cryoprecipitate), units of blood products transfused, and adverse clinical outcomes related to transfusion (acute kidney injury, infections, and death). Data will also be collected for future health-economics analyses.
Largely due to the limitations of existing evidence, however, such algorithms are rarely used in clinical practice. The proposed trial will provide sound, generalizable data on the effectiveness of a POC-based algorithm to guide their future use. An integrated blood management algorithm that employs POC coagulation tests will reduce blood product transfusions in cardiac surgery, thereby improving clinical outcomes.
Does an integrated blood transfusion algorithm that employs POC coagulation tests applied across a network of hospitals reduce blood transfusions and associated adverse outcomes in cardiac surgery?
研究概览
详细说明
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Alberta
-
Calgary、Alberta、加拿大、T2N 2T9
- Dr. Charles McAdams
-
Edmonton、Alberta、加拿大
- Blaine Achen
-
-
British Columbia
-
Vancouver、British Columbia、加拿大、V5Z 1M9
- Dr. Terry Waters
-
Vancouver、British Columbia、加拿大
- Dr. Sukhpal Brar
-
-
Manitoba
-
Winnipeg、Manitoba、加拿大、R2H 2A6
- Dr. H. Grocott
-
-
Ontario
-
Hamilton、Ontario、加拿大、L8N 3Z5
- Dr. Summer Syed
-
London、Ontario、加拿大、N6A 5A5
- Dr. Christopher Harle
-
Newmarket、Ontario、加拿大、L3Y 2P9
- Dr. Daniel Kim
-
Ottawa、Ontario、加拿大、K1Y 4W7
- Dr. D. Tran
-
Toronto、Ontario、加拿大、M4N 3M5
- Dr. F. Moussa
-
-
Quebec
-
Fleurimont、Quebec、加拿大、J1H 5N4
- Dr. E. Medicis
-
Sainte -Foy、Quebec、加拿大、G1V 4G5
- Dr. J. Bussieres
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Hospital Inclusion:
- Participating hospitals must not currently be using a POC-based blood conservation algorithm; must have an in-hospital RBC transfusion rate of > 35% and platelet or plasma transfusion rates of > 20%; must conduct > 600 cardiac surgeries employing CPB per year; and must have commitments from departments of Anesthesia, Cardiac Surgery, and Laboratory Medicine to support the study and to abide by the algorithm
- Blood transfusion algorithm instituted as standard-of-care at participating hospitals
- All adult (≥ 18 years) patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) will be included in the analysis.
Exclusion Criteria: Hospitals not meeting inclusion.
学习计划
研究是如何设计的?
设计细节
- 主要用途:诊断
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他:Transfusion Algorithm
Hospitals will be randomized to the intervention arm of the study in a stratified manner.
|
A transfusion algorithm based on point-of-care coagulation testing.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Point Of Care (POC) Transfusion Algorithm Cardiac Study
大体时间:2.5 years
|
The primary outcome measure will be the proportion of patients who receive any allogeneic red blood cell (RBC) transfusion from admission before surgery to end of follow-up.
|
2.5 years
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Transfusion
大体时间:7 days
|
Allogeneic blood products (platelets, plasma, cryoprecipitate) or coagulation factors (e.g., fibrinogen concentrate, factor VIIa), or undergo re-exploration; units of blood products transfused, nadir hemoglobin concentration (to identify changes in transfusion practice that may be unrelated to treatment of coagulopathy)
|
7 days
|
|
Blood loss
大体时间:24 hours
|
Chest-tube drainage at 6 and 24 hours after surgery
|
24 hours
|
|
Ventilation and hospital stay
大体时间:24 hours to 7 days
|
Duration of mechanical ventilation and length of stay in the ICU and hospital
|
24 hours to 7 days
|
|
Kidney injury
大体时间:48 hours
|
Incidence of acute kidney injury, defined as a ≥ 2-fold in increase in creatinine or new renal replacement therapy within 48 hours after surgery
|
48 hours
|
|
Post operative complications
大体时间:7 days
|
Arrhythmias, sternal infection, myocardial infarction, stroke, thromboembolic events, and death
|
7 days
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- 14-7495-A
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.